Skip to main content

Table 1 Baseline characteristics of the patients categorized according to remission at 12-month follow-up

From: Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis

Variable All patients (n = 35) Remission at follow-up p Valuea
   No (n = 15) Yes (n = 20)  
Age, years, mean (SD) 55 (14) 57 (15) 53 (14) 0.43
Female sex, n (%) 28 (80%) 15 (75%) 13 (87%) 0.39
Rheumatoid factor-positive, n (%) 26 (74%) 10 (67%) 16 (80%) 0.37
Anti-citrullinated protein antibody-positive, n (%) 27 (77%) 10 (67%) 17 (85%) 0.20
Smokers, n (%) 8 (23%) 5 (33%) 3 (15%) 0.20
Duration of symptoms, months, mean (SD) 6 (7) 6 (10) 6 (4) 0.89
Number of tender joints, 0–68, mean (SD) 7 (6) 10 (7) 6 (5) 0.040
Number of swollen joints, 0–66, mean (SD) 6 (5) 6 (4) 7 (6) 0.78
Erythrocyte sedimentation rate, mm/h, mean (SD) 19 (15) 22 (18) 16 (13) 0.32
Plasma C-reactive protein, mg/L, mean (SD) 7 (7) 6 (3) 8 (9) 0.41
White blood cell count, ×109/L, mean (SD) 6.9 (2.4) 7.5 (3.1) 6.5 (1.6) 0.23
Patient global assessment, 0–100-mm VAS, mean (SD) 40 (25) 54 (24) 31 (21) 0.0073
DAS28 score, mean (SD) 3.63 (1.14) 4.08 (1.19) 3.29 (1.01) 0.040
Number of DMARDs started, mean (range) 2.2 (0–3) 2.1 (1–3) 2.3 (0–3) 0.72
 Single DMARD, n 4 2 2  
 Combination of two DMARDs, n 13 9 4  
 Combination of three DMARDs, n 16 4 12  
 None, n 2 0 2  
  1. Abbreviations: VAS Visual analogue scale, DAS28 28-Joint Disease Activity Score, DMARD Disease-modifying antirheumatic drug
  2. a Significance of difference between No and Yes groups calculated using permutation test or chi-square test